Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
RADX
RADX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest RADX ETF News Today | Earnings, Events & Price Alerts
RADX News
Radiopharm's First Radiotherapeutic Agent Enters Clinical Trials
Feb 24 2026
Newsfilter
Radiopharm Theranostics Reports Interim Clinical Trial Results and Financial Update
Jan 28 2026
Newsfilter
Benzinga Market Update: Carnival, Caterpillar, Meta Among Stocks as Markets See Slight Increases
Dec 20 2025
Benzinga
Dow Declines by 50 Points; US Employment Increases by 64,000 in November
Dec 16 2025
Benzinga
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 16 2025
Benzinga
What’s Behind the 140% Surge in Radiopharm Theranostics Stock?
Dec 15 2025
Benzinga
Radiopharm's RAD 101 Achieves 92% MRI Concordance in Phase 2b Trial
Dec 15 2025
Newsfilter
Radiopharm Theranostics Granted Approval to Start Phase 1 Clinical Trial of RAD 402 (KLK3-mAb with Tb161) for Advanced Prostate Cancer
Nov 18 2025
Newsfilter
Deutsche Bank ADR Virtual Investor Conference: Presentations Accessible for Online Viewing
Nov 05 2025
Globenewswire
UPDATE -- Global Firms to Present Live Webcasts at Deutsche Bank’s Virtual Investor Conference for Depositary Receipts on November 4, 2025
Oct 31 2025
Globenewswire
Global Firms to Present Live Webcasts at Deutsche Bank's Virtual Investor Conference for Depositary Receipts on November 4, 2025
Oct 30 2025
Globenewswire
Radiopharm Theranostics Gets Green Light from Data Safety and Monitoring Committee to Fast-Track 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial
Oct 01 2025
Newsfilter
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
Jul 29 2025
Newsfilter
Radiopharm Reports FDA Clearance To Initiate First-in-human Phase 1 Trial Of RV-01
Jul 28 2025
NASDAQ.COM
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Jul 22 2025
Newsfilter
Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
Jun 04 2025
Newsfilter
Show More News
